Scientists test two forms of a new drug to see which is safer

NCT ID NCT07701083

Not yet recruiting Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This early-stage trial studies how healthy adults process two different liquid versions of the experimental drug eloralintide. The goal is to compare their safety and how the body absorbs and clears each version. Participants receive a single injection and are monitored for about 13 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eloralintide (also known as LY3841136), given as a single injection under the skin
What this could lead to: If successful, this study could help determine the safest way to give eloralintide in future trials for conditions like obesity or metabolic disease.
What could go wrong: This is an early, small study in healthy people, so results may not predict effects in patients. Side effects or poor tolerability could stop further development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fortrea Clinical Research Unit

Daytona Beach, Florida, 32117, United States

Contact Phone: •••-•••-••••

Contact
Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States

Contact Phone: •••-•••-••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.